Fulgent Genetics (NASDAQ:FLGT - Get Free Report) issued its earnings results on Friday. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.22, Briefing.com reports. Fulgent Genetics had a negative net margin of 59.39% and a negative return on equity of 1.81%. The business had revenue of $73.46 million for the quarter, compared to the consensus estimate of $71.26 million. During the same quarter last year, the firm posted ($0.01) EPS. The business's revenue for the quarter was up 14.0% compared to the same quarter last year. Fulgent Genetics updated its FY 2025 guidance to -0.650--0.65 EPS.
Fulgent Genetics Trading Down 4.8 %
NASDAQ:FLGT traded down $0.98 on Monday, reaching $19.56. The stock had a trading volume of 658,856 shares, compared to its average volume of 267,736. The company has a 50-day moving average of $17.53 and a 200 day moving average of $18.06. The stock has a market cap of $603.74 million, a P/E ratio of -3.54 and a beta of 1.36. Fulgent Genetics has a 12-month low of $14.57 and a 12-month high of $25.11.
Wall Street Analyst Weigh In
A number of research analysts have commented on the company. Piper Sandler reduced their price objective on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Raymond James reissued an "outperform" rating and set a $25.00 price target (up from $24.00) on shares of Fulgent Genetics in a research report on Monday. Finally, StockNews.com upgraded Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Wednesday, March 5th.
Check Out Our Latest Stock Report on Fulgent Genetics
Insider Transactions at Fulgent Genetics
In related news, CFO Paul Kim purchased 100,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the transaction, the chief financial officer now owns 348,282 shares of the company's stock, valued at $5,558,580.72. This represents a 40.28 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 31.76% of the company's stock.
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Recommended Stories
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
